CFL-137

CFL-137 (CAS No.: 708-06-5) is a small-molecule inhibitor characterized as a potent and selective KRas G12C inhibitor, placing it within the class of targeted modulators of oncogenic Ras signaling pathways widely studied in cancer biology. By covalently or selectively interacting with the mutant KRas G12C protein, CFL-137 is understood to suppress downstream signaling cascades such as the MAPK and PI3K pathways, thereby disrupting cellular proliferation and survival mechanisms associated with oncogenic transformation. Consistent with this mechanism, it exhibits notable antiproliferative activity and demonstrates anticancer effects in in vitro cellular models, with activity typically observed in the nanomolar to low micromolar concentration range depending on assay conditions and cell line context. CFL-137 is primarily utilized as a research tool for investigating KRas-driven tumorigenesis, particularly in lung cancer models harboring the G12C mutation, and for evaluating pathway inhibition, resistance mechanisms, and combination strategies in preclinical studies. Experimental applications may include biochemical assays, cell-based proliferation studies, and in vivo tumor models, where dosing and exposure parameters are determined by specific experimental designs and objectives.